The Regulatory Tug-of-War: Balancing Patient Access and Safety in Rare Cancer Treatments
The Debate Over Accelerated Approval Families and patient advocacy groups are intensifying their calls for the U.S. Food and Drug Administration (FDA) to overhaul its drug approval processes, arguing that rigid regulatory hurdles are denying terminally ill patients access to potentially life-saving treatments. As malignant melanoma and other rare cancers continue to claim lives, the…